Vedolizumab

Indication

First, second and third-line treatment of moderately to severely active Crohn's disease after prior therapy (NICE TA352)

NICE TA 352 - Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy

Red

Brand:

Entyvio

Nice TA:

352

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Gastro-intestinal system

Background

Vedolizumab is recommended by LSCMMG as a first, second or third line biologic option for treating moderately to severely active Crohn’s disease if: an anti-TNF has failed, cannot be tolerated or is contraindicated.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Gastroenterology Biologics Pathway Version 1.1

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Red	Red	Red	Red	Red	Red	Red	Red

What do the colours mean?

Last Updated: 01 - Jan - 2015

Breadcrumb

Vedolizumab

Indication

Background

Recommendation

Decisions of Lancashire local decision making groups